SEQUENTIAL THERAPY OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: NEW POSSIBILITIES
Open Access
- 30 September 2018
- journal article
- review article
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 14 (3) , 120-127-127
Abstract
Currently, doctors have at their disposal a number of drugs prolonging life of patients with castration-resistant prostate cancer (CRPC). The majority is approved for use as the 1st line therapy and, in absence of direct comparison, is considered potentially equally effective. Patients with CRPC need continuous treatment for suppression of disease progression resulting in sequential use of therapeutic agents. Modern standards and recommendations do not provide a clear algorithm for prescription, therefore an individual approach is necessary taking in account various factors of a particular case ranging from previous therapies to patients’ preferences. This article considers the most significant factors affecting CRPC therapy selection and ways of therapy optimization in compliance with the established treatment standards and taking into account the list of drugs approved for use in Russia.Keywords
This publication has 40 references indexed in Scilit:
- Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted TherapiesEuropean Urology, 2015
- Activity of Cabazitaxel After Docetaxel and Abiraterone Acetate Therapy in Patients With Castration-Resistant Prostate CancerClinical Genitourinary Cancer, 2014
- Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine AgentsEuropean Urology, 2014
- Androgen Receptor Splice Variants in the Era of Enzalutamide and AbirateroneDiscover Oncology, 2014
- Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trialThe Lancet Oncology, 2014
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2013
- Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100Cancer Research, 2012
- Characterising the castration-resistant prostate cancer population: a systematic reviewInternational Journal Of Clinical Practice, 2011
- Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1993